phenobarbital has been researched along with Cystic Fibrosis in 5 studies
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Based on the available data it seems that one may postulate the following conclusions: (1) that the distribution factors as well as changes in drug elimination capacities seem to play a role, perhaps with differing relative importance, during each of the maturational periods; (2) that the physicochemical properties of a drug and its dosage, as well as changes in the volume of distribution in children, in the course of certain disease states may have a significant effect on kinetics of drug disposition in the body; (3) that systemic clearance, a model independent parameter, rather than elimination half-life, a hybrid pharmacokinetic parameter, more accurately reflects elimination of some drugs from the body; (4) that each drug and every clinical situation may require the evaluation of the direct effect on pharmacokinetic processes, since general principles may not always apply; (5) that drug disposition studies should also be performed, if possible, on patients under actual clinical situations and receiving the usual therapeutic regime, and (6) that the half-life of colistin is independent of postnatal age which should serve as a warning not to generalize about drug excretion in the young infant." | 2.37 | Clinical pharmacokinetics of changes in drug elimination in children. ( Prandota, J, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bukowskyj, M | 1 |
| Nakatsu, K | 1 |
| Munt, PW | 1 |
| Stiehl, A | 1 |
| Javitt, NB | 1 |
| Prandota, J | 1 |
| Haschen, RJ | 1 |
3 reviews available for phenobarbital and Cystic Fibrosis
| Article | Year |
|---|---|
Theophylline reassessed.
Topics: Acidosis; Aging; Allopurinol; Animals; Anti-Bacterial Agents; Breast Feeding; Bronchodilator Agents; | 1984 |
Clinical pharmacokinetics of changes in drug elimination in children.
Topics: Adult; Anti-Bacterial Agents; Brain Injuries; Child; Child, Preschool; Colistin; Cystic Fibrosis; Di | 1985 |
[Progress in diagnostic enzymology].
Topics: Alcoholism; Aminopeptidases; Amylases; Aspartate Aminotransferases; Cholinesterases; Creatine Kinase | 1973 |
2 other studies available for phenobarbital and Cystic Fibrosis
| Article | Year |
|---|---|
[Treatment of cholestatic liver diseases with phenobarbital and ursodeoxycholic acid].
Topics: Cholestasis, Intrahepatic; Cystic Fibrosis; Female; Humans; Liver Diseases; Liver Function Tests; Ma | 1993 |
Cholestasis in infancy. Status report and conceptual approach.
Topics: alpha 1-Antitrypsin Deficiency; Anion Exchange Resins; Bacterial Infections; Bile; Bile Ducts; Bile | 1976 |